Τόμος 11 (1997) – Τεύχος 2 & 3 – Άρθρο 6 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 11 (1997) – Issue 2 & 3 – Article 6 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

1. National Hellenic Research Foundation, Institute of Organic and Pharmaceutical Chemistry, Vassileos Constantinou 48,116 35 Athens, Greece

2. Departments of Neurology and Neuroimmunology Research Unit, Hodassah, University Hospital and Hebrew University-Hadassah Medical School, Jerusalem, Israel

3. Department of Chemistry, University of Patras, Patra 260 50, Greece

2.        Staykova M, Goranov I, Nikolov T: L’ influence du cyclophosphamide sur le developement de EAE. Ann. Immunol. 129: 415-427 (1978)

3.        Schuller-Levis GB, Kozlowsky PB, Wisniewski HM: Cyclosporin A treatment of an induced attack in a chronic relapsing model of experimental allergic encephalomyelitis. Clin. Immunol. Immunopathol. 40: 244-252 (1986)

4.        Feurer C, Chow C, Borel F: Preventive and therapeutic effects of cyclosporine and valine-dihydrocyclosporin in chronin relapsing EAE in Lewis rats. Immunology 63: 219- 223 (1988)

5.        Lieder O, Reshef T, Beraund E, Ben-Nun A, Cohen TR: Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 239: 181-183 (1988)

6.        Stalhandske T, Eriksson E, Sandberg GM: A novel quinoline-carboxamide with interesting immunomodulating activity. Int. J. Immunopharmacol 4: 336 (1982)

7.         Kalland T, Alm G, Stalhandske T: Augmentation of mouse natural killer activity by LS-2616, a new immunomodulator. J Immunol 134: 3956-3961 (1985)

8.        Kalland T: Regulation of natural killer progenitors. Studies with a novel immunomodulator with distinct effects at the precursor level. J. Immunol. 144: 4472-4476 (1990)

9.        Kalland T: Effects of immunomodulator LS2616 on growth and metastasis of the immune B16-F10 melanoma. Cancer Res. 46: 3018-3022 (1986)

10.      Bback NG, Hohlan J, Slorach S, Fuman G: Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine Coxsackie virus B3 myocarditis. J. Immunol. 142: 3225-3228 (1989)

11.       Strober S, Kotzin B, Field E, et al.: Treament of autoimmune disease with TLI: cellular and humoral mechanisms. Ann. N.Y. Acad. Sci. 475: 285-295 (1986)

12.      Tarkowski A, Gunnarsson K, Nilsson LA, Lindholm L, Stalhandske T: Successful treatment of autoimmunity in MRL/J mice with LS 2616 a new immunomodulator. Arthritis Rhem. 29: 1405-1409 (1986)

13.      Tarkowski A, Gunnarsson K, Stalhandske T: Effects of LS-2616 administration upon the autoimmune disease of (NZHXNZW) F1 hybrid mice. Immunology 59: 589-594 (1986)

14.      Karussis DM, Lehman, D, Slavin, S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Ben-Nun A, Kalland T. Abramsky, O: Inhibition of Acute, Experimental Autoimmune Encephalomyelitis by the Synthetic Immunomodulator Linomide. Ann. Neuol. 34: 654-660 (1993)

15.      Karussis DM, Lehman D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Kalland T, Abramsky, O: Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. 90(14): 6400-6404 (1993)

16.      Karussis DM, Lehman Y, Wirguin R, Mizrachi-Koll Abramsky O, Brenner T: Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J. Neuroimmunol. 55:187-193 (1994)

17.       Karussis DM, Lehman D, Linde A, Gjostrup P, Abramsky O: Immunological evaluation of patients with secondary pro-gressive MS treated with linomide. Neurology 46: A252 (1996)

18.      Karussis DM, Meiner Z, Lehman D, Gomori JM, Schwarz A, Linde A, Gjorstrup P, Abramsky O: Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A pilot double-blind placebo controlled study with monthly MRI evaluation. Neurology (in press) (1996)

19.      Matsoukas J, Hondrelis A, Keramida M, Yamdagri R, Wu Q, Moore G, Mavromoustakos T, Makriyannis A. Role of the N-terminal Domain of ANG II and [Sar1] ANG II on Conformation and Activity: NMR Evidence for Aromatic Ring Clustering and Peptide Backbone Folding Compared to [Des^1,2,3] ANG (I. J. Biol. Chem. 269: 5303-5312 (1994)

20.      Mavromoustakos T, De-Ping Yang, Theodoropoulou E, Makriyannis A: Studies of the Conformational Properties of the Cannabinmimetic Aminoalkylindole Pravadoline Using NMR and Molecular Modeling. Eur. J. Med. Chem. 30: 227-234 (1995)